Discover the latest industry insights at the 2026 Annual Meeting through engaging educational and product-focused sessions. These presentations give exhibiting companies a platform to unveil ...
Guselkumab, administered every 4 or 8 weeks, is effective and safe in patients with active psoriatic arthritis who have had an inadequate response to only one prior TNF inhibitor.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results